SCHEMBL20914352

SCHEMBL20914352

COc1cccc2oc(-c3c(CC(=O)O)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2RL3 Q96RI0 2/20 0.35
▸ TNKS O95271 2/20 0.34
▸ TNKS2 Q9H2K2 2/20 0.34
▸ PARP2 Q9UGN5 2/20 0.34
▸ AKR1B1 P15121 2/20 0.33
▸ ARF6 P62330 3/20 0.33
▸ TOP2A P11388 1/20 0.33
▸ P2RY14 Q15391 1/20 0.33
▸ POLB P06746 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ APLNR P35414 1/20 0.32
▸ DHODH Q02127 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ MAT2A P31153 1/20 0.32
▸ EDNRB P24530 1/20 0.32
▸ ACACA Q13085 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914355 0.92 RXRA (0.35) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20913986 0.92 TNKS (0.35) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20913996 0.92 SMN1; SMN2 (0.38) F2RL3ARF6POLBMEN1ALDH1A1
SCHEMBL20913906 0.91 F2RL3 (0.39) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20913955 0.91 APLNR (0.34) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20914351 0.91 TNKS (0.35) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20914135 0.89 F2RL3 (0.35) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20913953 0.89 TNKS (0.36) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20819079 0.89 TNKS (0.38) F2RL3TNKSTNKS2PARP2ARF6
SCHEMBL20914203 0.88 TNKS (0.37) F2RL3TNKSTNKS2PARP2ARF6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 F2RL3 1469/4885TNKS 531/4885TNKS2 932/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 F2RL3 1469/4885TNKS 531/4885TNKS2 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback